Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). The gene discussed is AHR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.